Solventum Corporation (NYSE:SOLV) Receives $87.00 Consensus Target Price from Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $87.00.

A number of research analysts recently commented on SOLV shares. Piper Sandler restated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. BTIG Research raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Tuesday, December 2nd. Jefferies Financial Group initiated coverage on shares of Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th.

Solventum Stock Up 0.2%

NYSE SOLV opened at $80.23 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. The company has a market cap of $13.91 billion, a price-to-earnings ratio of 9.24, a PEG ratio of 8.45 and a beta of 0.25. The company has a 50 day moving average of $78.02 and a 200-day moving average of $74.96. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, equities research analysts expect that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has authorized a stock repurchase plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SOLV. Wellington Management Group LLP grew its holdings in shares of Solventum by 226.2% during the 1st quarter. Wellington Management Group LLP now owns 27,737 shares of the company’s stock valued at $2,109,000 after purchasing an additional 19,233 shares during the last quarter. CW Advisors LLC bought a new stake in shares of Solventum during the first quarter worth $312,000. Smartleaf Asset Management LLC increased its holdings in shares of Solventum by 193.4% during the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after buying an additional 352 shares in the last quarter. Comerica Bank increased its holdings in shares of Solventum by 39.7% during the first quarter. Comerica Bank now owns 77,725 shares of the company’s stock worth $5,910,000 after buying an additional 22,079 shares in the last quarter. Finally, FORA Capital LLC bought a new position in shares of Solventum in the 1st quarter valued at $676,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.